|
gptkb:DB09145
|
peak plasma concentration in 3-4 hours
|
|
gptkb:DB15054
|
Extensively metabolized to active nucleoside analog triphosphate
|
|
gptkb:CHEMBL3529
|
inhibits CYP3A4
|
|
gptkb:CHEMBL3529
|
inhibits CYP2D6
|
|
gptkb:DB11162
|
not systemically distributed
|
|
gptkb:CHEMBL1161
|
does not cross blood-brain barrier significantly
|
|
gptkb:DB11799
|
rapidly distributed and metabolized
|
|
gptkb:DB12173
|
prodrug, rapidly metabolized to active nucleoside analog
|
|
gptkb:DB01590
|
rapid absorption, low bioavailability, renal excretion
|
|
gptkb:DB00065
|
Onset 30-60 min, peak 2-4 h, duration 6-8 h
|
|
gptkb:DB12189
|
rapidly converted to active nucleoside analog GS-441524
|
|
gptkb:DB15101
|
Rapidly distributed and metabolized
|
|
gptkb:DB13162
|
extensively metabolized
|
|
gptkb:DB14148
|
prodrug, converted to active nucleoside triphosphate
|
|
gptkb:DB08868
|
rapid absorption, peak plasma concentration in 2-4 hours
|
|
gptkb:CHEMBL1161
|
low lipid solubility
|
|
gptkb:DB13904
|
rapidly metabolized to active nucleoside analog
|